A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo - PubMed (original) (raw)
. 2003 Dec 15;63(24):8912-21.
Zhenping Zhu, Dan Lu, Donna Marie Anderson, Marie Prewett, Daniel S Pereira, Rajiv Bassi, Rashed Abdullah, Andrea T Hooper, Henry Koo, Xenia Jimenez, Danielle Johnson, Robin Apblett, Paul Kussie, Peter Bohlen, Larry Witte, Daniel J Hicklin, Dale L Ludwig
Affiliations
- PMID: 14695208
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo
Douglas Burtrum et al. Cancer Res. 2003.
Abstract
The insulin-like growth factor I receptor (IGF-IR) is overexpressed in many diverse tumor types and is a critical signaling molecule for tumor cell proliferation and survival. Therapeutic strategies targeting the IGF-IR may therefore be effective broad-spectrum anticancer agents. Through screening of a Fab phage display library, we have generated a fully human antibody (A12) that binds to the IGF-IR with high affinity (4.11 x 10(-11) M) and inhibits ligand binding with an IC(50) of 0.6-1 nM. Antibody-mediated blockade of ligand binding to the IGF-IR inhibited downstream signaling of the two major insulin-like growth factor (IGF) pathways, mitogen-activated protein kinase and phosphatidylinositol 3'-kinase/Akt, in MCF7 human breast cancer cells. As a result, the mitogenic and proliferative potential of IGF-I and IGF-II were significantly reduced. A12 did not block insulin binding to the insulin receptor but could block binding to atypical IGF-IR in MCF7 cells. In addition, A12 was shown to induce IGF-IR internalization and degradation on specific binding to tumor cells, resulting in a significant reduction in cell surface receptor density. In xenograft tumor models in vivo, IGF-IR blockade by A12 was shown to occur rapidly, resulting in significant growth inhibition of breast, renal, and pancreatic tumors. Histological analysis of tumor sections demonstrated a marked increase in apoptotic tumor cells in antibody-treated animals. These results demonstrate that A12 possesses strong antitumor activity in vitro and in vivo and may therefore be an effective therapeutic candidate for the treatment of cancers that are dependent on IGF-IR signaling for growth and survival.
Similar articles
- Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN. Wang Z, et al. Clin Cancer Res. 2006 Aug 1;12(15):4755-65. doi: 10.1158/1078-0432.CCR-05-2691. Clin Cancer Res. 2006. PMID: 16899627 - Insulin-like growth factor-I receptor signaling blockade combined with radiation.
Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, Hicklin DJ, Harari PM. Allen GW, et al. Cancer Res. 2007 Feb 1;67(3):1155-62. doi: 10.1158/0008-5472.CAN-06-2000. Cancer Res. 2007. PMID: 17283150 - IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. Rowinsky EK, et al. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s. doi: 10.1158/1078-0432.CCR-07-1109. Clin Cancer Res. 2007. PMID: 17875788 Review. - Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H, Nilsson K. Jernberg-Wiklund H, et al. Adv Cancer Res. 2007;97:139-65. doi: 10.1016/S0065-230X(06)97006-7. Adv Cancer Res. 2007. PMID: 17419944 Review.
Cited by
- Role of Insulin-like Growth Factor-1 Receptor in Tobacco Smoking-Associated Lung Cancer Development.
Shahid A, Santos SG, Lin C, Huang Y. Shahid A, et al. Biomedicines. 2024 Mar 2;12(3):563. doi: 10.3390/biomedicines12030563. Biomedicines. 2024. PMID: 38540176 Free PMC article. Review. - IGF-1 Stimulates Glycolytic ATP Production in MCF-7L Cells.
Rajoria B, Zhang X, Yee D. Rajoria B, et al. Int J Mol Sci. 2023 Jun 16;24(12):10209. doi: 10.3390/ijms241210209. Int J Mol Sci. 2023. PMID: 37373357 Free PMC article. - Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target.
Liu G, Zhu M, Zhang M, Pan F. Liu G, et al. Cancers (Basel). 2023 Feb 17;15(4):1287. doi: 10.3390/cancers15041287. Cancers (Basel). 2023. PMID: 36831629 Free PMC article. Review. - Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma.
Kumar S, Pandey AK. Kumar S, et al. Curr Oncol. 2023 Jan 18;30(2):1363-1380. doi: 10.3390/curroncol30020105. Curr Oncol. 2023. PMID: 36826066 Free PMC article. Review. - The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target.
Lee JS, Tocheny CE, Shaw LM. Lee JS, et al. Life (Basel). 2022 Nov 29;12(12):1992. doi: 10.3390/life12121992. Life (Basel). 2022. PMID: 36556357 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous